• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在安慰剂对照的重度抑郁症临床试验中预测非特异性治疗反应的不同机器学习方法比较

Comparison of Different Machine Learning Methodologies for Predicting the Non-Specific Treatment Response in Placebo Controlled Major Depressive Disorder Clinical Trials.

作者信息

Gomeni Roberto, Bressolle-Gomeni Françoise

机构信息

Pharmacometrica, La Fouillade, France.

出版信息

Clin Transl Sci. 2025 Jan;18(1):e70128. doi: 10.1111/cts.70128.

DOI:10.1111/cts.70128
PMID:39807769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11729444/
Abstract

Placebo effect represents a serious confounder for the assessment of treatment effect to the extent that it has become increasingly difficult to develop antidepressant medications appropriate for outperforming placebo. Treatment effect in randomized, placebo-controlled trials, is usually estimated by the mean baseline adjusted difference of treatment response in active and placebo arms and is function of treatment-specific and non-specific effects. The non-specific treatment effect varies subject by subject conditional to the individual propensity to respond to placebo. This effect is not estimable at an individual level using the conventional parallel-group study design, since each subject enrolled in the trial is assigned to receive either active treatment or placebo, but not both. The objective of this study was to conduct a comparative analysis of the machine learning methodologies to estimate the individual probability of a non-specific treatment effect. The estimated probability is expected to support novel methodological approaches for better controlling effect of excessively high placebo response. At this purpose, six machine learning methodologies (gradient boosting machine, lasso regression, logistic regression, support vector machines, k-nearest neighbors, and random forests) were compared to the multilayer perceptrons artificial neural network (ANN) methodology for predicting the probability of individual non-specific treatment response. ANN achieved the highest overall accuracy among all methods tested. A fivefold cross-validation was used to assess performances and risks of overfitting of the ANN model. The analysis conducted without subjects with non-specific effect indicated a significant increase of signal detection with significant increase in effect size.

摘要

安慰剂效应在评估治疗效果时是一个严重的混杂因素,以至于开发出比安慰剂更有效的抗抑郁药物变得越来越困难。在随机、安慰剂对照试验中,治疗效果通常通过活性药物组和安慰剂组治疗反应的平均基线调整差异来估计,并且是治疗特异性和非特异性效应的函数。非特异性治疗效果因个体对安慰剂反应的倾向不同而因人而异。使用传统的平行组研究设计无法在个体水平上估计这种效应,因为参与试验的每个受试者要么被分配接受活性治疗,要么接受安慰剂,而不是两者都接受。本研究的目的是对机器学习方法进行比较分析,以估计非特异性治疗效果的个体概率。预计估计出的概率将支持新的方法,以更好地控制过高安慰剂反应的影响。为此,将六种机器学习方法(梯度提升机、套索回归、逻辑回归、支持向量机、k近邻和随机森林)与多层感知器人工神经网络(ANN)方法进行比较,以预测个体非特异性治疗反应的概率。在所有测试方法中,ANN的总体准确率最高。使用五重交叉验证来评估ANN模型的性能和过拟合风险。在没有非特异性效应受试者的情况下进行的分析表明,信号检测显著增加,效应大小也显著增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bca/11729444/1453d7a61bc7/CTS-18-e70128-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bca/11729444/84ef90cdf7bf/CTS-18-e70128-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bca/11729444/3fe754b6a1d3/CTS-18-e70128-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bca/11729444/2c059b3fc02d/CTS-18-e70128-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bca/11729444/1453d7a61bc7/CTS-18-e70128-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bca/11729444/84ef90cdf7bf/CTS-18-e70128-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bca/11729444/3fe754b6a1d3/CTS-18-e70128-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bca/11729444/2c059b3fc02d/CTS-18-e70128-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bca/11729444/1453d7a61bc7/CTS-18-e70128-g004.jpg

相似文献

1
Comparison of Different Machine Learning Methodologies for Predicting the Non-Specific Treatment Response in Placebo Controlled Major Depressive Disorder Clinical Trials.在安慰剂对照的重度抑郁症临床试验中预测非特异性治疗反应的不同机器学习方法比较
Clin Transl Sci. 2025 Jan;18(1):e70128. doi: 10.1111/cts.70128.
2
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses to treatment.基于模型的方法,使用基于人工智能的倾向加权方法估计安慰剂对照临床试验中的治疗效果,以考虑对治疗的非特异性反应。
J Pharmacokinet Pharmacodyn. 2024 Dec 10;52(1):5. doi: 10.1007/s10928-024-09950-7.
3
A novel artificial intelligence-based methodology to predict non-specific response to treatment.一种基于人工智能的新型方法,用于预测对治疗的非特异性反应。
Psychiatry Res. 2025 Jun;348:116506. doi: 10.1016/j.psychres.2025.116506. Epub 2025 Apr 19.
4
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
5
Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placebo.人工智能方法分析主要抑郁症障碍的安慰剂对照临床试验,考虑到个体对安慰剂的反应倾向。
Transl Psychiatry. 2023 Apr 29;13(1):141. doi: 10.1038/s41398-023-02443-0.
6
Predicting Antidepressant Treatment Response From Cortical Structure on MRI: A Mega-Analysis From the ENIGMA-MDD Working Group.基于MRI皮质结构预测抗抑郁治疗反应:ENIGMA-MDD工作组的一项荟萃分析
Hum Brain Mapp. 2025 Jan;46(1):e70053. doi: 10.1002/hbm.70053.
7
Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.探索性分析美国食品和药物管理局支持新药申请的主要抑郁症试验的疗效数据。
J Clin Psychiatry. 2011 Apr;72(4):464-72. doi: 10.4088/JCP.10m06191.
8
Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial.基于预处理症状和脑电图特征的机器学习模型评估对抑郁症成年患者抗抑郁治疗结局的预测:一项随机临床试验的预设二次分析。
JAMA Netw Open. 2020 Jun 1;3(6):e206653. doi: 10.1001/jamanetworkopen.2020.6653.
9
Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.在随机对照试验中,包含安慰剂组是否会影响对活性抗抑郁药治疗的反应?汇总和荟萃分析的结果。
J Clin Psychiatry. 2010 Mar;71(3):270-9. doi: 10.4088/JCP.08r04516blu. Epub 2010 Jan 26.
10
A new method for analyzing clinical trials in depression based on individual propensity to respond to placebo estimated using artificial intelligence.基于人工智能估计的个体对安慰剂反应倾向分析抑郁症临床试验的新方法。
Psychiatry Res. 2023 Sep;327:115367. doi: 10.1016/j.psychres.2023.115367. Epub 2023 Aug 2.

引用本文的文献

1
AI-NLME: A New Artificial Intelligence-Driven Nonlinear Mixed Effect Modeling Approach for Analyzing Longitudinal Data in Randomized Placebo-Controlled Clinical Trials.AI-NLME:一种用于分析随机安慰剂对照临床试验中纵向数据的新型人工智能驱动的非线性混合效应建模方法。
Clin Transl Sci. 2025 Sep;18(9):e70345. doi: 10.1111/cts.70345.

本文引用的文献

1
Using machine learning models to identify the risk of depression in middle-aged and older adults with frequent and infrequent nicotine use: A cross-sectional study.使用机器学习模型识别经常和不经常使用尼古丁的中年和老年人患抑郁症的风险:一项横断面研究。
J Affect Disord. 2024 Dec 15;367:554-561. doi: 10.1016/j.jad.2024.08.185. Epub 2024 Aug 31.
2
Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting.使用倾向评分加权法评估抑郁障碍中假阴性和真阴性临床试验,以解释受安慰剂反应影响的临床试验结果。
Transl Psychiatry. 2023 Dec 14;13(1):388. doi: 10.1038/s41398-023-02685-y.
3
A new method for analyzing clinical trials in depression based on individual propensity to respond to placebo estimated using artificial intelligence.
基于人工智能估计的个体对安慰剂反应倾向分析抑郁症临床试验的新方法。
Psychiatry Res. 2023 Sep;327:115367. doi: 10.1016/j.psychres.2023.115367. Epub 2023 Aug 2.
4
Landscape Analysis of the Application of Artificial Intelligence and Machine Learning in Regulatory Submissions for Drug Development From 2016 to 2021.2016年至2021年人工智能和机器学习在药物研发监管申报中的应用情况分析
Clin Pharmacol Ther. 2023 Apr;113(4):771-774. doi: 10.1002/cpt.2668. Epub 2022 Jun 16.
5
Using Artificial Intelligence-based Methods to Address the Placebo Response in Clinical Trials.使用基于人工智能的方法应对临床试验中的安慰剂反应。
Innov Clin Neurosci. 2022 Jan-Mar;19(1-3):60-70.
6
Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data.利用机器学习和综合遗传、临床及人口统计学数据优化抗抑郁药物反应的预测。
Transl Psychiatry. 2021 Jul 8;11(1):381. doi: 10.1038/s41398-021-01488-3.
7
Machine Learning: Algorithms, Real-World Applications and Research Directions.机器学习:算法、实际应用与研究方向。
SN Comput Sci. 2021;2(3):160. doi: 10.1007/s42979-021-00592-x. Epub 2021 Mar 22.
8
Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials.SPN-812(缓释维洛沙嗪)的早期反应可预测多动症儿科患者的疗效结果:四项随机临床试验的机器学习事后分析
Psychiatry Res. 2021 Feb;296:113664. doi: 10.1016/j.psychres.2020.113664. Epub 2021 Jan 5.
9
Success and efficiency of phase 2/3 adjunctive trials for MDD funded by industry: a systematic review.由行业资助的重度抑郁症2/3期辅助试验的成功率和效率:一项系统评价
Mol Psychiatry. 2020 Sep;25(9):1967-1974. doi: 10.1038/s41380-020-0646-3. Epub 2020 Jan 27.
10
Architectures and accuracy of artificial neural network for disease classification from omics data.基于组学数据的疾病分类的人工神经网络结构和准确性。
BMC Genomics. 2019 Mar 4;20(1):167. doi: 10.1186/s12864-019-5546-z.